Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$6.86

0.13 (1.93%)

, ICPT

Intercept

$90.75

-7.37 (-7.51%)

07:14
09/14/17
09/14
07:14
09/14/17
07:14

Intercept Ocaliva dynamics highlight PBC opportunity, says Oppenheimer

Oppenheimer analyst Jay Olson says the Dear Doctor letter for Intercept's (ICPT) Ocaliva raises awareness of unmet medical need for patients with primary biliary cholangitis, or PBC. Since patients with Child-Pugh B/C cirrhosis were not studied in Ocaliva trials, the analyst believes the FDA's collaboration with Intercept to leverage PK modeling for dosing guidance which is included in the label and emphasized in the Dear Doctor letter highlights the importance of providing novel treatments to PBC patients. Olson expects these events to have a positive impact on the treatment of all PBC patients, and says CymaBay (CBAY) may benefit from these dynamics. He reiterates an Outperform rating and $15 price target on CymaBay's shares.

CBAY

CymaBay

$6.86

0.13 (1.93%)

ICPT

Intercept

$90.75

-7.37 (-7.51%)

  • 25

    Sep

CBAY CymaBay
$6.86

0.13 (1.93%)

07/25/17
PIPR
07/25/17
NO CHANGE
Target $12
PIPR
Overweight
CymaBay price target raised to $12 from $6.50 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for CymaBay Therapeutics to $12 to reflect increasing value for seladelpar. Importantly, no liver transaminase signals nor drug-induced pruritus were observed in the "positive" Phase II data in 24 primary biliary cholangitis patients receiving seladelpar, the analyst contends. He reiterates an Overweight rating on CymaBay shares.
08/11/17
IFSG
08/11/17
DOWNGRADE
Target $13
IFSG
Outperform
CymaBay downgraded to Outperform from Strong Buy at IFS Securities
IFS Securities analyst David Bouchey downgraded CymaBay to Outperform from Strong Buy, saying he sees now as a good time to step back with additional news flow not expected to pick until 2018. He lowered his price target on CymaBay to $13 from $18.
08/18/17
RHCO
08/18/17
INITIATION
RHCO
Buy
CymaBay initiated with a Buy at SunTrust
SunTrust analyst Edward Nash started coverage of CymaBay with a $15 price target and a Buy rating. He is upbeat on the outlook for the company's seladelpar, a treatment for a rare liver disease called primary biliary cholangitis. According to the analyst ,the drug has "well defined approvable endpoints and a primed commercial opportunity,"
08/23/17
LEER
08/23/17
INITIATION
Target $12
LEER
Outperform
CymaBay initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started CymaBay with an Outperform rating and $12 price target, noting that the company is currently developing seladelpar for the lead indication of primary biliary cholangitis, an autoimmune disease that causes progressive destruction of the bile ducts in the liver.
ICPT Intercept
$90.75

-7.37 (-7.51%)

09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.
09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.
09/13/17
BMOC
09/13/17
NO CHANGE
BMOC
Intercept should be bought on weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.
09/13/17
JMPS
09/13/17
NO CHANGE
Target $150
JMPS
Outperform
Intercept letter doesn't change fundamental view of Ocaliva, says JMP Securities
JMP Securities analyst Liisa Bayko said the warning letter sent by Intercept to health care providers regarding post-marketing reports of liver issues and death in certain PBC patients highlights risks that were already known and doesn't change her fundamental view on Ocaliva. The analyst, who sees little read through to the ongoing Phase 3 REGENERATE trial in NASH patients and views yesterday's drop in Intercept shares as an overreaction, keeps an Outperform rating and $150 price target on the stock.

TODAY'S FREE FLY STORIES

HPQ

HP Inc.

$23.62

0.33 (1.42%)

14:06
01/19/18
01/19
14:06
01/19/18
14:06
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 22

    Jan

RENN

Renren

$10.96

-0.16 (-1.44%)

14:05
01/19/18
01/19
14:05
01/19/18
14:05
Options
Renren call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$3.66

0.03 (0.83%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
Tonix: Horsepox virus showed protection vs. lethal vaccinia infection in study »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$587.11

7.89 (1.36%)

, CIR

Circor

$53.40

1.12 (2.14%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
BlackRock reports 12.6% passive stake in Circor »

In a regulatory filing,…

BLK

BlackRock

$587.11

7.89 (1.36%)

CIR

Circor

$53.40

1.12 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 22

    Feb

VIA

Viacom

$39.70

1.85 (4.89%)

, FOXA

21st Century Fox

$36.18

-0.93 (-2.51%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
Box Office Battle: 'Jumanji,' 'The Post' expected to hold off '12 Strong' »

Still expected to remain…

VIA

Viacom

$39.70

1.85 (4.89%)

FOXA

21st Century Fox

$36.18

-0.93 (-2.51%)

LGF.B

Lionsgate

$33.25

0.41 (1.25%)

VIAB

Viacom

$33.95

1.99 (6.23%)

CMCSA

Comcast

$41.85

0.17 (0.41%)

CMCSK

Comcast

LGF.A

Lionsgate

$35.22

0.72 (2.09%)

TWX

Time Warner

$92.90

-0.07 (-0.08%)

DIS

Disney

$110.18

-0.24 (-0.22%)

SNE

Sony

$49.80

0.63 (1.28%)

FOX

21st Century Fox

$35.73

-0.76 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

BLK

BlackRock

$586.98

7.76 (1.34%)

, BXS

BancorpSouth

$34.90

0.35 (1.01%)

14:02
01/19/18
01/19
14:02
01/19/18
14:02
Hot Stocks
BlackRock reports 10.2% passive stake in BancorpSouth »

In a regulatory filing,…

BLK

BlackRock

$586.98

7.76 (1.34%)

BXS

BancorpSouth

$34.90

0.35 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 25

    Jan

14:00
01/19/18
01/19
14:00
01/19/18
14:00
General news
Action Economics Survey results: »

Action Economics Survey…

BASFY

BASF

$29.54

0.825 (2.87%)

, BAYRY

Bayer

$31.82

0.015 (0.05%)

13:57
01/19/18
01/19
13:57
01/19/18
13:57
Periodicals
Breaking Periodicals news story on BASF, Bayer »

Capitol Forum says BASF,…

BASFY

BASF

$29.54

0.825 (2.87%)

BAYRY

Bayer

$31.82

0.015 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 25

    Mar

13:55
01/19/18
01/19
13:55
01/19/18
13:55
General news
SF Fed moderate Williams said economic tailwinds »

SF Fed moderate Williams…

OCPNY

Olympus Corp

$38.27

-0.12 (-0.31%)

13:54
01/19/18
01/19
13:54
01/19/18
13:54
Hot Stocks
Judge grants new trial for Bigler Family vs. Olympus wrongful-death case »

A King County court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.99

0.6 (0.78%)

13:52
01/19/18
01/19
13:52
01/19/18
13:52
Periodicals
Citi plans to have post-Brexit trading hub running by year end, Bloomberg says »

Citigroup intends to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

CANF

Can-Fite BioPharma

$1.76

0.01 (0.57%)

13:50
01/19/18
01/19
13:50
01/19/18
13:50
Conference/Events
Can-Fite BioPharma participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

13:50
01/19/18
01/19
13:50
01/19/18
13:50
Options
VIX slips on a relatively quiet monthly expiration »

VIX slips on a relatively…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
01/19/18
01/19
13:50
01/19/18
13:50
General news
Oil Action: Baker-Hughes »

Oil Action: Baker-Hughes…

KMI

Kinder Morgan

$18.97

-0.045 (-0.24%)

13:45
01/19/18
01/19
13:45
01/19/18
13:45
Options
Post earnings premium seller collects $13M in KinderMorgan »

Post earnings premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$91.92

1.61 (1.78%)

13:45
01/19/18
01/19
13:45
01/19/18
13:45
Options
Incyte call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

PRQR

ProQR Therapeutics

13:31
01/19/18
01/19
13:31
01/19/18
13:31
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CMC

Commercial Metals

$24.83

-0.26 (-1.04%)

13:30
01/19/18
01/19
13:30
01/19/18
13:30
Options
Second day of call buying in Commercial Metals »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLEX

Flex

$19.61

0.17 (0.87%)

13:25
01/19/18
01/19
13:25
01/19/18
13:25
Options
Flex call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CSCO

Cisco

$41.30

0.1 (0.24%)

13:22
01/19/18
01/19
13:22
01/19/18
13:22
Periodicals
Cisco expands Spectre, Meltdown investigation to nine more products, CRN reports »

Cisco added nine more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$119.50

2.18 (1.86%)

13:21
01/19/18
01/19
13:21
01/19/18
13:21
Periodicals
Chronicle review shows Universal Health hospital failed to watch patients »

Universal Health's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.26

0.16 (0.09%)

, AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

13:20
01/19/18
01/19
13:20
01/19/18
13:20
Periodicals
Spotify to offer news, political coverage to lure listeners, Bloomberg says »

Spotify will begin…

AAPL

Apple

$179.26

0.16 (0.09%)

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

GOOG

Alphabet

$1,129.79

-2.19 (-0.19%)

GOOGL

Alphabet Class A

$1,135.97

-3.13 (-0.27%)

SIRI

SiriusXM

$5.47

0.03 (0.55%)

P

Pandora

$4.49

-0.005 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

$NSD

NASDAQ Market Internals

13:17
01/19/18
01/19
13:17
01/19/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$50.57

-0.31 (-0.61%)

13:16
01/19/18
01/19
13:16
01/19/18
13:16
Technical Analysis
Technical Earnings Preview: PetMed Express at life highs before news »

The stock is at life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

$NYE

NYSE Market Internals

13:16
01/19/18
01/19
13:16
01/19/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.